Regulation - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 206 results

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

23-12-2014

Swiss biotech company Actelion has submitted a New Drug Application to the US Food and Drug Administration…

ActelionCardio-vascularPharmaceuticalRegulationselexipagSwitzerland

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

18-12-2014

US pharma company Pozen has received a second complete response letter from the US Food and Drug Administration…

Cardio-vascularPharmaceuticalPozenRegulationUSAYosprala 325/40Yosprala 81/40

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

08-12-2014

The Scottish Medicines Consortium has decided to grant access to Gazyvaro (obinutuzumab), manufactured…

AdempasBayerCardio-vascularGazyvaroOncologyPharmaceuticalRegulationRoche

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

Actelion submits selexipag for EMA marketing authorization in PAH

Actelion submits selexipag for EMA marketing authorization in PAH

03-12-2014

Swiss biotech firm Actelion has submitted a centralized Marketing Authorization Application to the European…

ActelionCardio-vascularEuropePharmaceuticalRegulationselexipag

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

Mylan confirms first-to-file patent challenge relating to Brevibloc

25-11-2014

US generic drugmaker Mylan today confirmed that it and several subsidiaries have been sued by US drugmaker…

Baxter InternationalBreviblocCardio-vascularGenericsLegalMylanPatentsRegulationUSA

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

21-11-2014

The European Medicines Agency has reviewed angina medication Corlentor/Procoralan (ivibradine), manufactured…

Cardio-vascularEuropePharmaceuticalProcoralanRegulationServier

EMA PRAC’s recommendations to reduce risk of heart problems with ivabradine

09-11-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a…

AmgenCardio-vascularEuropeivabradinePharmaceuticalProcoralanRegulationServier

US FDA advisory panel backs Daiichi Sankyo’s Savaysa for stroke risk and SEE

03-11-2014

A US Food and Drug advisory panel has voted in favor of the use of Japanese pharma major Daiichi Sankyo’s…

Cardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulationSavaysaUSA

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

14-09-2014

Shares of US biotech firm Amarin Corp tanked 23.7% to $1.38 on Friday in heavy trading, when the company…

AmarinCardio-vascularGlaxoSmithKlineLovazaPharmaceuticalRegulationVascepa

FDA Advisory votes against approving Actavis nebivolol/valsartan combo

FDA Advisory votes against approving Actavis nebivolol/valsartan combo

10-09-2014

Ireland-based generic drug major Actavis yesterday confirmed that the US Food and Drug Administration's…

ActavisCardio-vascularnebivololPharmaceuticalRegulationUSAvalsartan

Vifor reports positive results from Ferinject study for chronic heart failure

Vifor reports positive results from Ferinject study for chronic heart failure

01-09-2014

Switzerland-based iron specialist Vifor Pharma says its Ferinject (ferric carboxymaltose) has met its…

Cardio-vascularChronic heart failureFerinjectPharmaceuticalRegulationSwitzerlandVifor Pharma

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

31-08-2014

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationResearch

Amgen files for US approval of cholesterol drug evolocumab

28-08-2014

USA-based Amgen, the world's leading independent biotech firm, has filed a Biologics License Application…

AmgenBiotechnologyCardio-vascularChemistryevolocumabFamilial hypercholesterolemiaHealth Medical PharmaHigh cholesterolPCSK9RegulationUSA

1 to 25 of 206 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top